DOCSLIB.ORG

United Kingdom

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United Kingdom UNITED KINGDOM A & D Instruments Ltd Abertec Ltd Adams Business Associates Abingdon Science Park, Abingdon, Oxford OX 14 Old College King St, Aberystwyth, Dyfed SY23 Kelvin House, Totteridge Ave, High Wycombe, 3YS. 2AX. Bucks HP\3 6XG. Tel: 0235 5504201 0800 616140 Tel: 0970 622385 Telex: 35181 aby ucw Tel: 0494 465244 Fax: 0494 446788 Fax: 0235 550485 Fax: 0970 622959 Offer services in biotechnology including Supply semi-micro, analytical, general, industrial Involved in technology transfer from University of international market analysis, management and and moisture balances as well as density meters. Wales Aberystwyth. Capabilities include genetics, implementation of projects (including mergers and genetic engineering, bioproducts and acquisitions) and business development and biotransformations, biochemistry, plant and animal marketing programmes. Subsidiary offices now & A J Beveridge metabolism, biomass measurement, biosensing, established in Belguim, France and Spain. 5 Bonnington Road Lane, Leith, Edinburgh EH6 process control, tissue culture. Also undertakes 5BP. consultancy and collaborative research. Tel: 031 5535555 Fax: 031 5546068 ADC Systems Supply laboratory products. Gronant, Caernarfon, Gwynedd LL54 5BY. ABR Foods Ltd Tel: 0286 77148 Sallow Road, Weldon Industrial Estate, Corby Designs and manufactures analytical and Aaston Ltd NorthantsNNI7 \JX. preparative equipment for pathology laboratories Tel: 0536 65291 Telex: 34695 3 Abbas Business Centre, Itchen Abbas, Winchester, based on photometric determinations and robotic Fax: 0536 402228 HampshireS021IBQ. systems. Tel: 0980 6\0 391 Fax: 0980 610 898 Process wheat for the production of vital gluten as See Aaston Inc, MA, US. well as producing other related starch products, syrups and animal feed ingredients. Investigating ADM Ingredients Ltd opportunities for production of fermentation Church Manorway, Erith, Kent DA8 I DL. ABB Kent-Taylor Ltd substrates from grains. Tel: 0322 44300 Fax: 0322437536 Howard Rd, Eaton Socon, St Neots, Cambridgshire Citric Division supplies citric acid, citrates, lactic PEI93EU. acid and gluconates. Protein and Lecithin Division Tel: 0480475321 Fax: 0480217948 Acacia Chemicals Ltd Worsley Bridge Rd, Lower Sydenham, London supplies a complete range of soya proteins and Manufacture a wide range of electrodes and sensors SE265HD. lecithins. for laboratory and industrial use. Tel: 0816504801 Developing biological pest control systems. Advanced Biocentre Ltd Aber Instruments 2 Brandon House, West St, Somerton, Somerset Aberystwyth Science Park, Aberystwyth, Dyfed Acer Environmental TAI17PS. SY233AH. Tel: 0458 74073 Telex: 94012204 abio Tel: 0970 615284 Fax: 0970 615455 A Division of Acer Consultants Ltd Fax: 0458 74079 Designs and manufactures electronic Acer House, Howard Court, Manor Park, Runcorn Produces and markets plants produced by tissue instrumentation. Products include an instrument for WA7ISJ. culture and micropropagation including cuttings measuring biomass concentrations eg yeast cell Tel: 0928 579955 Fax: 0928 579206 from own nursery in Portugal. Undertake contract concentration in fermenters. Provide environmental services with an emphasis on growing and research at laboratory in the UK and EIA, audits, waste management and contaminated associate laboratory in India. Carrying out research Aberdeen University land, risk assessment and analytical services. on methods of micropropagation, in vitro breeding and plant health. Department of Microbiology Aberdeen AB9IFX. ACO Electronics Ltd Tel: 022440241 Unit 3, Manor Farm Business Park, Wendy, Advanced Biotechnologies Royston, Herts SG8 OHW. Investigating the efficiency of energy utilization in Unit 7, Mole Business Park, Leatherhead KT22 0223 208222 81573 acoele microbial growth as well as aspects of the Tel: Telex: 7BA. overproduction of metabolites and the Fax: 0223 208150 Tel: 0372 360 123 Fax: 0372 363 263 transformation of ammonia based fertilizers. Also Supply light sources including microscope and Undertake polyclonal antibody production. Supply investigating commercial uses for chitin and CCTV illumination systems and infrared equipment. biological reagents, polyc1onal antibodies, chitinase as well as mechanisms of inhibition of monoclonal antibodies, DNA probes, DNA chitin synthesis. AD2Ltd sequencing reagents, DNA synthesis enzymes, modifying enzymes, restriction enzymes, total RNA Aston Science Park, Birmingham, W Midlands B7 Aberdeen University Research and isolation reagents, immunoassays and plastic 4BJ. consumables. Industrial Services Ltd (AURIS) Tel: 021 3590981 Fax: 021 3590433 23 St Machar Drive, Aberdeen AB2 I RY, Scotland. Offers consultancy in licensing patented technology Tel: 0224 272853 Telex: 73458 in the life sciences. Advanced Laboratory Techniques Fax: 0224487658 I Clarincarde Gardens, Tunbridge Wells, Kent. Tel: 0892 30483 Provide a wide range of research, consultancy and Adam Equipment Co Ltd training services in environmental management and Supplies diagnostic reagents for radioimmunoassay Third Ave, Denbigh Industrial Estate, Bletchley, planning, environmental impact assessment and including antiserums, standards and reagents, as Milton Keynes MK I lEW. coastal and offshore seabed surveys. Also provide well as ki ts and reagents for other diagnostic tests 0908274545 0908 641339 microbiological and chemical analytical services Tel: Fax: and haematology. Also supplies disposable and have a team of economic consultants. Supply analytical and precision balances. laboratory products. 244 J. Coombs et al., The International Biotechnology Directory 1995 © Palgrave Macmillan, a division of Macmillan Publishers Limited 1994 UNITED KINGDOM Part II Advanced Protein Products Ltd extensive listing of antibodies, neurochemicals, AI Cambridge Ltd Unit 18H, Premier Partnership Estate, Leys Rd, molecular biology products, detection systems and London Road, Pampisford, Cambridge CB2 4EF. Brockmoor, Brierley Hill, West Midlands DY5 3UP. equipment mainly directed towards neuroscience Tel: 0223 834 420 Fax: 0223 835 050 and signal transduction research. Exclusive Tel: 0384263862 Telex: 338427 Supplies gas chromatography systems and Fax: 0384480351 European distributor for Transduction Laboratories, US, and worldwide for Sternberger Monoclonals, accessories, including sample handling equipment Manufacturers of high quality sterile serum, plasma, US, Eugene Tech International, US and Medisera, serum albumins, proteins and growth factors. Sweden. Air Products pic Develop specialized media for cell studies and separation. Undertake contract production, contract Hersham Place, Molesey Rd, Hersham, Walton on Thames, Surrey KTl2 4RZ. and collaborative research and development, Affinity Chromatography Ltd manufacture, filtration and freeze drying. Tel: 0932 249200 Telex: 36511 Freeport, Ballasalla, Isle of Man. Fax: 0932 249565 Tel: 0624 823519 Fax: 0624 824957 Advanced Separation Technologies Langmuir Road, Bargeddie, Baillieston, Lanarkshire Research Centre: 307 Huntingdon Rd, Girton, G697TS. Langton House, 53 Langton Rd, East Molesey, Cambridge CB3 OJX. Tel: 041 772 2311 Fax: 041 771 0423 Surrey KT8 2HX. Tel: 0223 277192 Fax: 0223 277502 Tel: 0819410845 Fax: 0819410845 Supply bulk industrial gases including oxygen, Develop and manufacture a diverse range of nitrogen and carbon dioxide. Member of the Air Offers consultancy in separation and membrane Products and Chemical Group, US. technology. selective and robust chromatography media for the purification ofbiomolecules suitable for use in research, preparative and large-scale affinity Akzo Chemie UK Ltd Advanced Technologies (Cambridge) Ltd separations. GMP manufacturing facility and Pier Road, Gillingham, Kent ME7 I RL. 210 Cambridge Science Park, Milton Rd, experienced R&D, QA and production teams are Tel: 0634 51141 Telex: 96159 Cambridge CB44WA. available for custom design and manufacture of Tel: 0223 420284 Fax: 0223 423448 adsorbents suitable for use in the production of Manufactures fatty acids and derivatives as well as biopharmaceuticals, custom synthesis and contract surfactants and other products of Akzo NV, Investigate and develop methods for regenerating Netherlands. plants in culture including protoplast culture, shoot research. organogenesis and somatic embryogenesis. Anther culture is used to create true breeding plants from Aldrich Chemical Co crosses between different plant lines as part of the Agricultural Development Advisory Service The Old Brickyard, New Rd, Gillingham, Dorset molecular gene mapping programme. Genetic ADAS-Worcester SP84JL. fingerprinting and mapping by RFLP (Restriction Whittington Rd, Worcester WR5 2LQ. Tel: 0747 82221110800 7171 81 Fragment Length Polymorphism), and gene transfer Tel: 0905 763355 Fax: 0905 763428 Telex: 417238 aldrch Fax: 0747 823779 to produce transgenic plants are used in a tree Now an independent body. Suppliers of 36000 items including fme organic and improvement programme, for example with inorganic chemicals, biochemicals, stains and dyes, eucalyptus, and other plant breeding projects. Has HPLC and anhydrous solvents, ion exchange resins developed transgenic plants with resistance to Agricultural Genetics Company Ltd and adsorption media, atomic absorption standards, parasitic nematodes. Church Street, Thriplow, Nr Royston, Herts SG8 deuterated compounds, polymers, pure elements, 7RE. laboratory equipment, scientific glassware and books. Subsidiary of Sigma-Aldrich Corporation, Advanced Technology Management Tel: 0763 208 448 Fax: 0763 208 881 PO
Load more

Recommended publications
  • Beecham Group PLC and Another V Triomed (Pty) Ltd [2002] 4 All SA 193 (SCA)
    Beecham Group PLC and another v Triomed (Pty) Ltd [2002] 4 All SA 193 (SCA) Division: Supreme Court of Appeal Date: 19 September 2002 Case No: 100/01 Before: Harms, Scott, Mpati, Conradie JJA and Jones AJA Sourced by: PR Cronje Summarised by: D.Harris Parallel Citation: 2003 (3) SA 639 (SCA) . Editor's Summary . Cases Referred to . Judgment . [1] Intellectual property ­ Trade marks ­ Registration of shape as trade mark ­ Where shape is not intended to be used to distinguish owner's products from those of another, it cannot be regarded as a trade mark ­ Application for expungement from trade marks register therefore allowed. Editor's Summary Both parties involved in the present matter were players in the pharmaceutical industry. The Appellants sought the upholding of a trade mark for the shape of a tablet, and a finding that the Respondent had infringed the trade mark. The Respondent imported a tablet with the same composition and shape as that of the Appellants. In the court a quo, the Respondent applied for the expungement from the trade mark register of the shape trade mark. The Appellants launched a counter­application for relief for trade mark infringement. The latter application failed while that of the Respondent succeeded. Held ­ Interested parties may apply to court for the removal of an entry wrongly made or remaining on the trade mark register. The first question posed by the Court was whether the Appellants' shape mark constituted a trade mark in terms of section 10(1) of the Trade Marks Act 194 of 1993 ("the Act").
    [Show full text]
  • Genscript Product Catalog 2013-2014 Genscript Product Catalog
    GenScript Product Catalog 2013-2014 GenScript Product Catalog www.genscript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854USA Tel: 1-732-885-9188 / 1-732-885-9688 Toll-Free Tel: 1-877-436-7274 Fax: 1-732-210-0262 / 1-732-885-5878 Email: [email protected] Nucleic Acid Purification and Analysis Business Development Tel: 1-732-317-5088 PCR PCR and Cloning Email: [email protected] Protein Analysis Antibodies 2013-2014 Peptides Welcome to GenScript GenScript USA Incorporation, founded in 2002, is a fast-growing biotechnology company and contract research organization (CRO) specialized in custom services and consumable products for academic and pharmaceutical research. Built on our assembly-line mode, one-stop solutions, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of products and services at the most competitive prices in the industry to meet your research needs every day. Over the years, GenScript’s scientists have developed many innovative technologies that allow us to maintain our position at the cutting edge of biological and medical research while offering cost-effective solutions for customers to accelerate their research. Our advanced expertise includes proprietary technology for custom gene synthesis, OptimumGeneTM codon optimization technology, CloneEZ® seamless cloning technology, FlexPeptideTM technology for custom peptide synthesis, BacPowerTM technology for protein expression and purification, T-MaxTM adjuvant and advanced nanotechnology for custom antibody production, as well as our ONE-HOUR WesternTM detection system and eStain® protein staining system. GenScript offers a broad range of reagents, optimized kits, and system solutions to help you unravel the mysteries of biology. We also provide a comprehensive portfolio of customized services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,353,350 B2 Kobayashi Et Al
    US009353350B2 (12) United States Patent (10) Patent No.: US 9,353,350 B2 Kobayashi et al. (45) Date of Patent: May 31, 2016 (54) METHOD FOR PRODUCING MULTIPOLAR 2012fO149053 A1 6, 2012 Yoshida et al. CELL 2013,0323,776 A1 12/2013 Yoshida et al. 2015. OO18286 A1* 1/2015 Kobayashi et al. .......... 514, 19.3 (71) Applicant: TOAGOSEICO.,LTD., Tokyo (JP) FOREIGN PATENT DOCUMENTS (72) Inventors: Nahoko Kobayashi, Tsukuba (JP); CN 1763O82 A 4/2006 Tetsuhiko Yoshida, Tsukuba (JP); Yuki DE 102009021681 A1 11, 2010 Kobayashi, Fujisawa (JP) WO O3O24408 A2 3, 2003 WO O3O37172 A2 5, 2003 WO 2004.005472 A2 1, 2004 (73) Assignee: TOAGOSEICO. LTD., Tokyo (JP) WO 2004/020457 A2 3, 2004 WO 2007/004869 A2 1, 2007 (*) Notice: Subject to any disclaimer, the term of this WO 2007056188 A1 5/2007 patent is extended or adjusted under 35 WO 2008/081812 A1 T 2008 WO WO 2009,093692 A1 T 2009 U.S.C. 154(b) by 0 days. WO WO 2011/O13698 A1 2, 2011 (21) Appl. No.: 14/366,971 WO WO 2011/O13699 A1 2, 2011 (22) PCT Filed: Dec. 20, 2012 OTHER PUBLICATIONS Paradis-Bleau et al., “Peptide inhibitors of the essential cell division (86). PCT No.: PCT/UP2O12AO83110 protein FtsA'. Protein Engineering, Design & Selection, 2005, pp. S371 (c)(1), 85-91, vol. 18, No. 2, Oxford University Press. (2) Date: Jun. 19, 2014 Paradis-Bleau et al., “Identification of Pseudomonas aeruginosa FtsZ. peptide inhibitors as a tool for development of novel antimicro bials”, Journal of Antimicrobial Chemotherapy, Jun. 2004, pp.
    [Show full text]
  • Explaining Corporate Success Abstract
    Explaining corporate success: Britain’s best performing firms, 1949-1985 D.M. Higgins, S. Toms The York Management School Abstract The paper synthesises theories of competitive advantage in a dynamic framework to explain the determinants of corporate success. A model is presented linking the firm’s resource audit and dynamic capabilities with the rate of market growth. For the purposes of testing the model, an examination of the performance of all British quoted companies during the period is conducted with reference to achieved long run average rates of return on capital employed. The best performing firms are analysed in more detail and their strategies mapped according to the model criteria. Conclusions are then drawn on the possible strategies for achieving long run corporate success in terms of above average financial returns. Correspondence Steven Toms Joint Editor: Business History Professor of Accounting and Finance and Head of School The York Management School Sally Baldwin Buildings University of York York YO10 5DD Tel: (44) 1904-434122 Fax: (44) 1904-433 431 Email: [email protected] http://www.york.ac.uk/management/staff/StaffProfiles/SToms.htm 1 Explaining corporate success: Britain’s best performing firms, 1949-1985 1. Introduction Competitive advantage and more specifically sustained competitive advantage and its determinants, has become an important research topic in the business and management and industrial organisation literatures. Sustained competitive advantage (SCA) implies not just achieving superior returns, but achieving them over a protracted period of time. It is therefore surprising that the overwhelming majority of this literature has not explored the notion of sustained competitive advantage from a historical perspective.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research
    Peptide Handbook A Guide to Peptide Design and Applications in Biomedical Research First Edition www.GenScript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA Phone: 1-732-885-9188 Toll-Free: 1-877-436-7274 Fax: 1-732-885-5878 Table of Contents The Universe of Peptides Reliable Synthesis of High-Quality Peptides Molecular structure 3 by GenScript Characteristics 5 Categories and biological functions 8 Analytical methods 10 Application of Peptides Research in structural biology 12 Research in disease pathogenesis 12 Generating antibodies 13 FlexPeptideTM Peptide Synthesis Platform which takes advantage of the latest Vaccine development 14 peptide synthesis technologies generates a large capacity for the quick Drug discovery and development 15 synthesis of high-quality peptides in a variety of lengths, quantities, purities Immunotherapy 17 and modifications. Cell penetration-based applications 18 Anti-microorganisms applications 19 Total Quality Management System based on multiple rounds of MS and HPLC Tissue engineering and regenerative medicine 20 analyses during and after peptide synthesis ensures the synthesis of Cosmetics 21 high-quality peptides free of contaminants, and provides reports on peptide Food industry 21 solubility, quality and content. Synthesis of Peptides Diverse Delivery Options help customers plan their peptide-based research Chemical synthesis 23 according to their time schedule and with peace of mind. Microwave-assisted technology 24 ArgonShield™ Packing eliminates the experimental variation caused by Ligation technology 26 oxidization and deliquescence of custom peptides through an innovative Recombinant technology 28 Modifications packing and delivery technology. 28 Purification 30 Expert Support offered by Ph.D.-level scientists guides customers from Product identity and quality control 31 peptide design and synthesis to reconstitution and application.
    [Show full text]
  • CEM Peptide Synthesis Brochure
    Unparalleled Peptide Synthesis cempeptides.com Contents CEM Overview 2 Innovations in Microwave Peptide Synthesis 2 Founding Fathers 3 Corporate Legacy Chemistry Technologies 4 HE-SPPS 6 CarboMAXTM 8 One Pot Coupling/Deprotection Peptide Synthesizers 10 Sequential vs Parallel 11 Synthesizer Comparison 12 Discover BioTM 12 Liberty LiteTM 13 Liberty BlueTM 13 Liberty Blue HT12TM 14 Liberty PRIMETM 16 Accessories & Upgrades Peptide Cleavage 17 Razor® SPPS Reagents 18 Fmoc Amino Acids 19 Oxyma Pure 19 Resins (ProTide™, Polystyrene) Large Scale Microwave Peptide Synthesis 22 Liberty PRO™ Customers 24 Testimonials 25 Support CEM Overview Innovations in Microwave Peptide Synthesis 1978 CEM Corporation founded as a new company, based on microwave laboratory instrumentation 2001 CEM launches a single mode microwave system for chemical synthesis 2003 CEM develops the world’s first automated microwave peptide synthesizer1 2007 CEM publishes research for optimized methods for aspartimide formation and epimerization under microwave SPPS2 2013 Liberty Blue™ peptide synthesizer developed based on High Efficiency Solid Phase Peptide Synthesis (HE-SPPS) 2014 HE-SPPS methodology published3 2016 CEM launches new universal load resins eliminating the need for pre-loaded resins historically used 2016 CEM offers the world’s first large-scale microwave peptide synthesis, with capabilities of up to 500 grams of a purified peptide, in a single batch 2016 CEM develops improved carbodiimide coupling methods for peptide synthesis at elevated temperature (CarboMAX™) 2017 CEM develops a novel one-pot coupling/ deprotection process reducing SPPS cycle time and waste usage (Liberty PRIME™) Founding Fathers (circa 1980) Chemist: Dr. Michael J. Collins (Middle) Electrical Engineer: Ron Goetchius (Left) Mechanical Engineer: Bill Cruse Jr.
    [Show full text]
  • Government Gazette Republic of Namibia
    GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$16.68 WINDHOEK- 2 September 1996 No. 1396 CONTENTS TRADE MARKS .............................................................................................................................. APPLICATIONS FOR REGISTRATION OF TRADE MARKS IN NAMIBIA (Applications accepted in terms of Act No. 48 of 1973) '\ Any person who has grounds for objection to any of the following trade marks, may, within the prescribed time, lodge Notice of Opposition on form SM6 con­ tained in the Second Schedule to the Trade Marks Rules in Namibia, 1973. The prescribed time is two months after the date of advertisement. This period may on application be extended by the Registrar. Where the Gazette is issued late, the period of opposition will count as from the date of issue and a notice relating thereto will be displayed on the public notice board in the Trade Marks Registry. Formal opposition should not be lodged until after notice has been given by letter to the applicant for registration so as to afford him an opportunity of withdrawing his application before the expense of preparing the Notice of Opposition is in­ curred. Failing such notice to the applicant an opponent may not succeed in ob­ taining an order for costs. "B" preceding the number indicates Part B of the Trade Mark Register. Neither the office mentioned hereunder nor Central Bureau Services (Pty) Ltd., acting on behalf of the Government of Namibia, guarantee the accuracy of this publication or undertake any responsibility for errors or omissions or their conse­ quences. E.T. KAMBOUA REGISTRAR OF TRADE MARKS FOR NAMIBIA 2 Government Gazette 2 September 1996 No. 1396 TRADE MARKS REMOVED FROM 1 JULY 1992 TO 30 JUNE 1996 NO.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Honorary Graduates
    Honorary Graduates (Chronological list) The names of deceased graduates are printed in italics. Master of Arts (MA) George Harris Thomson, Secretary-Treasurer of the Royal College of Science and Technology from 1947 to 1964, Registrar of the University from 1964 to 1966 July 1966 Charles Geoffrey Wood, University Librarian March 1967 William B Paton, County Librarian, Lanarkshire - First Head of the Scottish School of Librarianship, Scottish College of Commerce, 1946-50 April 1972 Gustav Heiberg, Chief of Division, Norwegian Ministry of Foreign Affairs July 1975 Charles Stewart, formerly Depute Bursar (Finance) in the University Administration Oct 1975 Louis McGougan, Bursur of the University of Strathclyde March 1976 Duncan Matheson, formerly Director of Physical Education in the University July 1983 Walter Underwood, formerly Planning Consultant to the University July 1983 Zbigniew Byszewski, former Consul-General for Poland in Scotland June 1986 John Turner, Organist to the University and Glasgow Cathedral July 1990 Susan Wighton, who worked as a nurse in Palestinian refugee camps July 1990 Andrew Miller, Director of Libraries, City of Glasgow District Council July 1990 Tommy Orr, former University Security Controller July 1990 James Arnold, Director and Village Manager, Lanark New Town Nov 1990 Graham Douglas, Draughtsman, Royal Commission on Ancient Building and Historical Monuments of Scotland July 1992 Yvonne Carol Grace Murray, Athlete May 1995 Master of Science (MSc) Ronald Ewart Nicoll, Professor of Urban Planning March 1967
    [Show full text]
  • Annual Report 2018 CORPORATE INFORMATION
    2018 ANNUAL REPORT Genscript Biotech Corporation (the “Company” or “Genscript”, together with its subsidiaries referred to as the “Group”) is a well-established global biotech company, which has consolidated its leading position in the gene synthesis service market with recognized stature in synthetic biology application areas . The Company’s mission is to “Make the Human and Nature Healthier through Biotechnology” by establishing a leading innovative protein and antibody engineering platform and striving for opportune breakthroughs in the fields of cell and gene therapies and industrial enzymes for the benefit of mankind. The Group is a well-recognised life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. The broad and integrated life sciences research and application service and product portfolio comprises four segments that are all incubated internally, deeply rooted in our proprietary gene synthesis technology and strongly supported by our advanced protein and antibody engineering competence, namely, (i) bio-science services and products, (ii) biologics development services, (iii) industrial synthetic biology products, and (iv) cell therapy. The bio-science services and products are primarily used by scientists and researchers for conducting fundamental life sciences research, translational biomedical research, and early stage pharmaceutical development. Its biologics development services are used by biopharmaceutical and biotech companies for the development of therapeutic antibodies, and gene or cell therapy products with an integrated platform. Its synthetic biology products are used by industry users of industrial enzymes, such as those in the food and feed industries.
    [Show full text]
  • 94771408.Pdf
    VSB — TECHNICAL UNIVERSITY OF OSTRAVA FACULTY OF ECONOMICS DEPARTMENT OF FINANCE Zhodnocení finanční pozice společnosti GlaxoSmithKline, a.s. Evaluation of Financial Position of the Company GlaxoSmithKline plc. Student: Xinran Chen Supervisor of the bachelor thesis: Ing. Ingrid Petrová, Ph.D. Ostrava 2017 Content 1 Introduction ......................................................................................................................... 4 2 Description of the Financial Analysis Methodology ........................................................... 6 2.1 Goal of financial analysis ......................................................................................... 6 2.2 Source of data for financial analysis ......................................................................... 7 2.2.1 Balance sheet .................................................................................................. 7 2.2.2 Income statement ............................................................................................ 9 2.2.3 Cash flow statement ..................................................................................... 10 2.3 Common-size analysis ............................................................................................ 12 2.3.1 Vertical common-size analysis ..................................................................... 12 2.3.2 Horizontal common-size analysis ................................................................ 13 2.4 Financial ratio analysis ..........................................................................................
    [Show full text]